Ozempic, the drug whose researchers have been awarded

Ozempic is a drug that is indicated for the treatment of type 2 diabetes that has not been adequately controlled so that it works as a complement to diet and exercise, according to its technical sheet prepared by the Spanish Agency for Medicines and Health Products ( AEMPS CIMA).

• It is also indicated when metformin treatment, a medication that works as a controller of the amount of glucose in the blood, is contraindicated because it generates adverse effects in the patient.

• On some occasions Ozempic can also be combined as a complement or added to other medical treatments related to diabetes.

Context. The researchers behind this drug have been awarded the 2024 Princess of Asturias Award for Scientific and Technical Research for the track record of their findings in advancing diabetes and obesity.

• These are the researchers Daniel J. Drucker, Joel F. Habener, Jens Juul Holst and Svetlana Mojsov who have developed this field since the 1970s.

• Jeffrey M. Friedman, also awarded, discovered in 1994 the hormone leptin, which acts on the region of the brain that controls appetite and satiety, reducing it, according to an article in the scientific journal Hospital Nutrition.

• In 2023 the magazine Science named Ozempic as one of the greatest scientific breakthroughs of that year.

Ozempic, a means against diabetes and obesity. The drug Ozempic works as a treatment for type 2 diabetes and also as a treatment for obesity.
In Sinc magazine, they explain that when the sugar level decreases, the liver releases glucose that rises, generating insulin and this insulin helps reduce excess sugar. In addition, semaglutide, another of the principles of this medication, works by reducing appetite and producing a feeling of satiety which, in turn, works as an aid in the weight loss process.